The Health Care Select Sector SPDR exchange-traded fund has gained 1.2% in 2024, lagging the S&P 500’s 24% gain. Health insurers are generally best avoided now (United Health might be an exception), but there are other opportunities. Two companies with GLP-1 weight loss drugs that might be buying opportunities now are Amgen and Eli Lilly.